This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 8874 |
intensive care | 8199 |
coronavirus disease | 6711 |
critically ill | 6408 |
risk factors | 6163 |
novel coronavirus | 5802 |
respiratory syndrome | 5148 |
mechanical ventilation | 4930 |
severe acute | 4805 |
ill patients | 4765 |
health care | 4752 |
care unit | 4685 |
respiratory distress | 4148 |
stem cell | 3912 |
mg kg | 3777 |
severe covid | 3629 |
respiratory failure | 3430 |
mean age | 3303 |
distress syndrome | 3290 |
systematic review | 3279 |
bone marrow | 3248 |
clinical characteristics | 3148 |
control group | 3105 |
cancer patients | 3012 |
hospitalized patients | 2955 |
significantly higher | 2949 |
one patient | 2886 |
cord uid | 2876 |
doc id | 2876 |
clinical trials | 2851 |
septic shock | 2784 |
cohort study | 2763 |
united states | 2714 |
critical care | 2708 |
blood pressure | 2663 |
respiratory tract | 2605 |
increased risk | 2599 |
two groups | 2582 |
high risk | 2525 |
statistically significant | 2507 |
cell transplantation | 2495 |
patients admitted | 2482 |
significant difference | 2417 |
heart failure | 2414 |
syndrome coronavirus | 2397 |
mortality rate | 2365 |
median age | 2350 |
among patients | 2291 |
peripheral blood | 2277 |
public health | 2244 |
clinical features | 2230 |
immune response | 2229 |
patients received | 2197 |
case report | 2193 |
emergency department | 2179 |
two patients | 2121 |
clinical trial | 2093 |
adverse events | 2083 |
infectious diseases | 2057 |
years old | 2032 |
risk factor | 2032 |
patients treated | 2028 |
clinical practice | 2013 |
ng ml | 1999 |
mg dl | 1975 |
lung injury | 1967 |
retrospective study | 1953 |
patients undergoing | 1930 |
acquired pneumonia | 1913 |
lung cancer | 1867 |
side effects | 1865 |
may also | 1851 |
patients receiving | 1845 |
adult patients | 1824 |
significant differences | 1811 |
patients without | 1805 |
infection control | 1805 |
breast cancer | 1804 |
clinical course | 1771 |
controlled trial | 1765 |
renal failure | 1727 |
icu admission | 1704 |
case series | 1684 |
cytokine storm | 1683 |
infected patients | 1681 |
observational study | 1673 |
lung disease | 1628 |
computed tomography | 1621 |
organ failure | 1605 |
immune system | 1602 |
logistic regression | 1593 |
present study | 1588 |
world health | 1583 |
informed consent | 1571 |
diabetes mellitus | 1560 |
performed using | 1553 |
patients infected | 1545 |
epithelial cells | 1543 |
icu patients | 1540 |
university hospital | 1528 |
hospital stay | 1525 |
inflammatory response | 1501 |
randomized controlled | 1501 |
ct scan | 1498 |
hospital mortality | 1493 |
pulmonary disease | 1477 |
health organization | 1458 |
disease severity | 1444 |
higher risk | 1443 |
reactive protein | 1430 |
viral infections | 1429 |
nervous system | 1411 |
myocardial infarction | 1407 |
hematopoietic stem | 1404 |
stem cells | 1392 |
clinical outcomes | 1390 |
patients may | 1375 |
overall survival | 1362 |
heart disease | 1346 |
least one | 1345 |
pg ml | 1336 |
respiratory symptoms | 1335 |
three patients | 1332 |
viral load | 1332 |
severe disease | 1330 |
prospective study | 1329 |
chest ct | 1327 |
cardiac arrest | 1317 |
significantly lower | 1316 |
patient care | 1316 |
transplant recipients | 1314 |
liver disease | 1310 |
pediatric patients | 1306 |
rights reserved | 1302 |
viral infection | 1299 |
whole blood | 1290 |
cardiovascular disease | 1277 |
flow cytometry | 1259 |
differential diagnosis | 1252 |
cd cd | 1252 |
virus infection | 1247 |
blood transfusion | 1241 |
blood donors | 1235 |
blood flow | 1227 |
cystic fibrosis | 1211 |
gene expression | 1207 |
pulmonary embolism | 1207 |
renal function | 1204 |
healthcare workers | 1199 |
factors associated | 1199 |
retrospective cohort | 1199 |
chain reaction | 1191 |
lymph nodes | 1185 |
care units | 1180 |
study period | 1178 |
convalescent plasma | 1177 |
important role | 1177 |
protective equipment | 1176 |
coronary artery | 1172 |
heart rate | 1167 |
converting enzyme | 1165 |
elderly patients | 1163 |
staphylococcus aureus | 1159 |
polymerase chain | 1157 |
hospital admission | 1154 |
lung function | 1152 |
general population | 1152 |
disease control | 1150 |
four patients | 1147 |
chronic obstructive | 1145 |
statistical analysis | 1140 |
lymph node | 1140 |
middle east | 1137 |
cell lines | 1132 |
median time | 1131 |
patients underwent | 1129 |
rheumatoid arthritis | 1125 |
new york | 1124 |
blood samples | 1120 |
red blood | 1118 |
liver failure | 1115 |
primary care | 1110 |
blood cell | 1101 |
endothelial cells | 1101 |
infectious disease | 1100 |
adverse effects | 1098 |
previous studies | 1097 |
oxygen saturation | 1089 |
signifi cant | 1087 |
nk cells | 1086 |
within days | 1075 |
personal protective | 1071 |
brain injury | 1070 |
cd cells | 1070 |
clinical data | 1070 |
severe sepsis | 1068 |
long term | 1066 |
obstructive pulmonary | 1065 |
multivariate analysis | 1061 |
type diabetes | 1061 |
platelet count | 1057 |
five patients | 1055 |
severe cases | 1046 |
body weight | 1044 |
kidney injury | 1044 |
replacement therapy | 1036 |
abdominal pain | 1036 |
consecutive patients | 1035 |
mental health | 1035 |
medical center | 1032 |
study design | 1031 |
coronavirus pneumonia | 1028 |
antibiotic therapy | 1028 |
critical illness | 1016 |
clinical presentation | 1016 |
east respiratory | 1013 |
urinary tract | 1010 |
sample size | 1001 |
physical examination | 992 |
acute kidney | 992 |
cardiac surgery | 991 |
acute lung | 990 |
medical records | 988 |
clinical manifestations | 987 |
blood cells | 986 |
liver transplantation | 983 |
magnetic resonance | 982 |
immune responses | 979 |
associated pneumonia | 974 |
nucleic acid | 970 |
positive patients | 968 |
inflammatory cytokines | 968 |
ischemic stroke | 964 |
pregnant women | 959 |
care workers | 944 |
regression analysis | 943 |
within hours | 937 |
hand hygiene | 935 |
central nervous | 934 |
mechanically ventilated | 932 |
lower respiratory | 930 |
clinical symptoms | 927 |
confirmed covid | 926 |
mortality rates | 925 |
ml kg | 923 |
tract infections | 921 |
significantly increased | 919 |
type i | 918 |
influenza virus | 917 |
poor prognosis | 915 |
may lead | 915 |
data suggest | 914 |
patients hospitalized | 913 |
trauma patients | 913 |
disease progression | 913 |
kidney disease | 912 |
organ dysfunction | 905 |
year old | 904 |
host disease | 902 |
patients presenting | 899 |
prostate cancer | 895 |
lopinavir ritonavir | 895 |
growth factor | 893 |
patients showed | 891 |
author funder | 880 |
apache ii | 878 |
granted medrxiv | 877 |
study group | 877 |
many patients | 876 |
included patients | 876 |
retrospective analysis | 872 |
copyright holder | 871 |
family members | 870 |
median follow | 869 |
upper respiratory | 868 |
one case | 868 |
left ventricular | 868 |
icu stay | 866 |
chronic hepatitis | 864 |
healthy controls | 862 |
results suggest | 860 |
symptom onset | 860 |
commonly used | 859 |
case reports | 857 |
significantly associated | 855 |
multiple organ | 850 |
nitric oxide | 849 |
inclusion criteria | 849 |
old male | 848 |
venous thromboembolism | 848 |
body mass | 847 |
randomized clinical | 847 |
respiratory rate | 846 |
predictive value | 843 |
membrane oxygenation | 840 |
atrial fibrillation | 839 |
day mortality | 838 |
risk patients | 837 |
ml min | 836 |
patients requiring | 831 |
coronavirus infection | 828 |
data collection | 825 |
tract infection | 823 |
clinical signs | 822 |
myocardial injury | 819 |
determine whether | 819 |
imaging findings | 817 |
per day | 817 |
signifi cantly | 817 |
high levels | 815 |
extracorporeal membrane | 813 |
necrosis factor | 813 |
free survival | 811 |
six patients | 809 |
significant increase | 809 |
may occur | 805 |
controlled trials | 803 |
high mortality | 801 |
multiple sclerosis | 797 |
blood products | 796 |
fi ndings | 793 |
social distancing | 791 |
acute gvhd | 789 |
central venous | 787 |
pao fio | 785 |
sickle cell | 783 |
mass index | 782 |
invasive ventilation | 781 |
pilot study | 780 |
age years | 779 |
kg day | 777 |
older adults | 774 |
one year | 774 |
primary outcome | 773 |
chronic gvhd | 773 |
conditioning regimen | 770 |
patient population | 768 |
patients died | 766 |
clinical outcome | 765 |
weight loss | 763 |
operating room | 762 |
respiratory disease | 752 |
monoclonal antibody | 751 |
pulmonary hypertension | 751 |
respiratory viruses | 751 |
oxidative stress | 750 |
blood group | 744 |
significantly reduced | 744 |
significantly different | 742 |
respiratory infections | 741 |
white blood | 741 |
colorectal cancer | 739 |
patients developed | 737 |
may result | 735 |
minimally invasive | 733 |
serum levels | 733 |
two cases | 730 |
medical history | 729 |
fi rst | 727 |
clinical studies | 726 |
patients will | 726 |
cardiac output | 721 |
acute phase | 721 |
tumor necrosis | 721 |
chest pain | 718 |
confirmed cases | 716 |
cell count | 714 |
red cell | 711 |
may cause | 710 |
blood loss | 710 |
soft tissue | 709 |
design method | 707 |
oxygen therapy | 706 |
bronchoalveolar lavage | 705 |
ventilated patients | 705 |
innate immune | 703 |
viral rna | 703 |
respiratory syncytial | 702 |
recent studies | 702 |
liver function | 701 |
odds ratio | 699 |
arterial blood | 699 |
confidence interval | 699 |
widely used | 697 |
hong kong | 697 |
older patients | 696 |
analysis showed | 695 |
national health | 693 |
pulmonary function | 693 |
renal replacement | 692 |
old female | 691 |
even though | 686 |
authors declare | 686 |
pulmonary fibrosis | 684 |
high dose | 683 |
version posted | 682 |
age group | 679 |
severe pneumonia | 677 |
study showed | 675 |
clinical management | 675 |
statistical significance | 674 |
syncytial virus | 674 |
respiratory infection | 674 |
seven patients | 672 |
peer review | 669 |
poor outcome | 667 |
cardiac injury | 667 |
immunocompromised patients | 666 |
spinal cord | 666 |
smooth muscle | 664 |
severe patients | 664 |
viral pneumonia | 664 |
palliative care | 663 |
early diagnosis | 663 |
ct scans | 662 |
may help | 660 |
cell carcinoma | 660 |
pseudomonas aeruginosa | 659 |
blood components | 659 |
patients presented | 652 |
electron microscopy | 651 |
image quality | 646 |
higher mortality | 646 |
artery disease | 646 |
antibiotic treatment | 645 |
total number | 645 |
renal disease | 644 |
year period | 644 |
test results | 643 |
treated patients | 642 |
clinical improvement | 641 |
medical care | 641 |
blood glucose | 640 |
blood cultures | 639 |
identifi ed | 638 |
immune cells | 636 |
cytokine release | 636 |
well tolerated | 635 |
recent study | 635 |
first case | 634 |
increased mortality | 633 |
blood donation | 632 |
prospective cohort | 631 |
eight patients | 631 |
invasive mechanical | 630 |
normal range | 629 |
bacterial infection | 629 |
cord blood | 629 |
first time | 629 |
large number | 627 |
old man | 627 |
pulmonary artery | 627 |
physical activity | 626 |
patients diagnosed | 625 |
incubation period | 625 |
several studies | 625 |
serum creatinine | 624 |
cell proliferation | 623 |
multiple myeloma | 623 |
tidal volume | 623 |
bacterial infections | 622 |
care providers | 621 |
extracellular vesicles | 621 |
may contribute | 621 |
resonance imaging | 620 |
gastrointestinal tract | 619 |
gold standard | 619 |
surgical procedures | 616 |
patient safety | 614 |
pleural effusion | 614 |
previously reported | 614 |
results showed | 613 |
infected pneumonia | 610 |
medical staff | 609 |
hospital discharge | 609 |
supportive care | 609 |
combination therapy | 608 |
outcome measures | 606 |
early stage | 605 |
nk cell | 601 |
acute renal | 601 |
decision making | 600 |
significant reduction | 599 |
standard deviation | 599 |
severe respiratory | 597 |
type ii | 595 |
single center | 594 |
pet ct | 594 |
per patient | 594 |
vital signs | 593 |
small bowel | 592 |
sars coronavirus | 592 |
liver injury | 591 |
mg ml | 591 |
mm hg | 590 |
ethics committee | 590 |
monoclonal antibodies | 590 |
randomized trial | 589 |
traumatic brain | 588 |
mg day | 588 |
patients aged | 588 |
chronic kidney | 587 |
measured using | 587 |
univariate analysis | 585 |
prognostic factors | 585 |
allogeneic hematopoietic | 585 |
intravenous immunoglobulin | 584 |
made available | 584 |
body temperature | 583 |
laboratory tests | 583 |
average age | 581 |
one study | 581 |
laboratory findings | 581 |
cell line | 580 |
recent years | 580 |
american college | 576 |
marrow transplantation | 576 |
ct findings | 576 |
per year | 575 |
study population | 575 |
lupus erythematosus | 574 |
two different | 574 |
summary conclusion | 573 |
fatality rate | 572 |
exclusion criteria | 570 |
old woman | 570 |
amino acid | 570 |
hepatocellular carcinoma | 569 |
also found | 568 |
hbv dna | 568 |
antiviral therapy | 567 |
preliminary results | 567 |
metabolic syndrome | 565 |
last years | 565 |
data analysis | 564 |
diagnostic criteria | 561 |
cell transplant | 559 |
cumulative incidence | 558 |
older age | 557 |
dendritic cells | 557 |
nosocomial infections | 557 |
disseminated intravascular | 557 |
case studies | 556 |
acute myocardial | 555 |
wide range | 555 |
surgical treatment | 554 |
septic patients | 554 |
survival rate | 552 |
treatment options | 552 |
intravascular coagulation | 552 |
systemic lupus | 552 |
descriptive study | 551 |
health system | 550 |
healthcare professionals | 549 |
pulmonary edema | 549 |
healthy volunteers | 549 |
higher levels | 548 |
high incidence | 547 |
inflammatory markers | 547 |
month period | 545 |
respiratory support | 545 |
time pcr | 543 |
tumor cells | 543 |
care medicine | 543 |
may play | 542 |
sore throat | 542 |
literature review | 542 |
another study | 542 |
independently associated | 541 |
tested positive | 541 |
sofa score | 541 |
ebola virus | 540 |
emergency room | 539 |
independent risk | 539 |
high prevalence | 538 |
chest radiograph | 537 |
cov infection | 537 |
treatment group | 537 |
diabetic patients | 536 |
arterial pressure | 534 |
animal models | 534 |
antimicrobial therapy | 533 |
mr imaging | 532 |
new coronavirus | 532 |
regression model | 532 |
patients suffering | 531 |
continuous variables | 531 |
retrospective review | 530 |
streptococcus pneumoniae | 529 |
common cause | 528 |
complete remission | 528 |
nine patients | 525 |
kidney transplant | 524 |
chart review | 524 |
surgical intervention | 524 |
effective treatment | 524 |
age groups | 523 |
sars patients | 523 |
observational studies | 522 |
task force | 522 |
inflammatory bowel | 521 |
cell death | 521 |
current study | 521 |
mononuclear cells | 521 |
infl ammatory | 520 |
endotracheal intubation | 519 |
negative pressure | 518 |
three groups | 518 |
severely ill | 516 |
clinically significant | 516 |
tertiary care | 515 |
lung transplantation | 515 |
randomised controlled | 514 |
twice daily | 514 |
allogeneic stem | 514 |
cell surface | 514 |
may provide | 513 |
surgical patients | 511 |
will also | 510 |
low risk | 509 |
patient outcomes | 508 |
supplemental oxygen | 506 |
hiv infection | 506 |
prone positioning | 506 |
airway pressure | 505 |
first days | 505 |
learning objectives | 505 |
transplant patients | 504 |
lymphocyte count | 503 |
clinical findings | 502 |
early detection | 500 |
machine learning | 500 |
study aimed | 499 |
aged years | 499 |
blood gas | 499 |
study included | 497 |
allergic rhinitis | 497 |
autoimmune diseases | 497 |
patients included | 497 |
family history | 496 |
summary conclusions | 496 |
acute care | 496 |
time points | 494 |
protein expression | 494 |
interquartile range | 494 |
analyzed using | 493 |
asymptomatic patients | 493 |
insulin resistance | 493 |
virus disease | 492 |
two weeks | 491 |
control study | 491 |
lung tissue | 491 |
significantly decreased | 490 |
disease activity | 490 |
categorical variables | 490 |
small number | 488 |
baseline characteristics | 488 |
function tests | 487 |
blood bank | 487 |
infection prevention | 487 |
mental status | 487 |
interstitial lung | 487 |
practice guidelines | 487 |
medrxiv preprint | 486 |
real time | 486 |
bowel disease | 485 |
venous thrombosis | 485 |
plasma levels | 485 |
molecular weight | 484 |
white matter | 484 |
prospective observational | 484 |
chronic liver | 484 |
cancer cells | 483 |
nasal cannula | 483 |
may require | 482 |
significant correlation | 482 |
bacterial pneumonia | 482 |
background case | 481 |
infl ammation | 480 |
results indicate | 480 |
clinically relevant | 480 |
previously described | 479 |
overall mortality | 478 |
viral replication | 478 |
high level | 478 |
control measures | 478 |
diagnostic accuracy | 478 |
findings suggest | 477 |
united kingdom | 476 |
significant improvement | 476 |
release syndrome | 476 |
mrna expression | 475 |
may increase | 474 |
assessed using | 473 |
multicenter study | 473 |
related mortality | 473 |
gastrointestinal symptoms | 472 |
exact test | 472 |
higher incidence | 471 |
cell activation | 470 |
natural killer | 470 |
young children | 470 |
western blot | 470 |
low dose | 469 |
cognitive impairment | 469 |
lactate dehydrogenase | 469 |
china clinical | 468 |
phase ii | 468 |
analysis revealed | 467 |
obese patients | 467 |
patient characteristics | 466 |
subarachnoid hemorrhage | 465 |
ex vivo | 465 |
see table | 464 |
escherichia coli | 464 |
endothelial cell | 464 |
electronic medical | 463 |
infectious complications | 462 |
solid organ | 461 |
significant decrease | 461 |
international license | 460 |
patient developed | 460 |
healthcare system | 460 |
general hospital | 459 |
will need | 459 |
fungal infections | 458 |
systemic inflammation | 458 |
three months | 458 |
patients compared | 458 |
systemic inflammatory | 457 |
postoperative complications | 457 |
congenital heart | 457 |
future studies | 457 |
endothelial dysfunction | 456 |
class i | 456 |
diffuse alveolar | 455 |
mesenchymal stem | 455 |
sectional study | 454 |
right ventricular | 453 |
positive results | 453 |
vein thrombosis | 452 |
patients required | 451 |
iu ml | 451 |
different types | 451 |
ii score | 451 |
national institute | 449 |
phase iii | 449 |
severe illness | 448 |
days post | 447 |
ejection fraction | 447 |
angiotensin ii | 446 |
dimer levels | 445 |
cell lung | 445 |
gvhd prophylaxis | 445 |
york city | 444 |
cerebrospinal fluid | 444 |
patient management | 443 |
adverse reactions | 443 |
two years | 443 |
ards patients | 443 |
skeletal muscle | 443 |
study clinical | 442 |
cardiovascular risk | 440 |
glass opacities | 440 |
human immunodeficiency | 440 |
ill covid | 439 |
healthcare providers | 439 |
immunodeficiency virus | 439 |
acute rejection | 438 |
leading cause | 438 |
response rate | 436 |
underlying disease | 436 |
results show | 435 |
respiratory system | 434 |
drug administration | 434 |
group i | 434 |
one hundred | 433 |
disease patients | 433 |
red cells | 433 |
healthy subjects | 433 |
graft failure | 432 |
medical treatment | 432 |
review board | 431 |
status epilepticus | 428 |
institutional review | 428 |
well known | 427 |
term follow | 426 |
adipose tissue | 426 |
fl uid | 426 |
pandemic influenza | 426 |
proinflammatory cytokines | 426 |
less likely | 426 |
viral shedding | 425 |
commercially available | 424 |
interstitial pneumonia | 424 |
related complications | 424 |
cell lymphoma | 423 |
th day | 422 |
radiation therapy | 422 |
mean arterial | 422 |
months post | 421 |
copd patients | 421 |
cardiogenic shock | 421 |
elevated levels | 420 |
male patients | 419 |
demographic data | 419 |
adult inpatients | 418 |
noninvasive ventilation | 418 |
acute liver | 417 |
cytokine production | 416 |
spike protein | 416 |
laboratory data | 413 |
hospitalized covid | 413 |
quality control | 412 |
retrospectively reviewed | 411 |
positive correlation | 411 |
severe ards | 411 |
clinical diagnosis | 409 |
cell disease | 409 |
blood count | 408 |
care facilities | 407 |
blood vessels | 405 |
renal transplant | 405 |
serum samples | 404 |
aft er | 404 |
scoring system | 404 |
thrombotic complications | 404 |
close contact | 404 |
disease course | 404 |
nosocomial infection | 403 |
general anesthesia | 403 |
connective tissue | 403 |
days later | 402 |
also observed | 402 |
mouse model | 402 |
survival rates | 401 |
selected patients | 401 |
written informed | 400 |
ace expression | 400 |
gastric cancer | 400 |
patients using | 399 |
ten patients | 399 |
linear regression | 399 |
myeloid leukemia | 398 |
natural history | 398 |
adverse event | 398 |
severe asthma | 398 |
diagnostic tests | 398 |
antiviral treatment | 397 |
currently available | 397 |
prognostic value | 397 |
resistant staphylococcus | 397 |
en el | 397 |
allogeneic hsct | 396 |
chronic diseases | 396 |
primary endpoint | 396 |
working group | 395 |
collected data | 395 |
elective surgery | 395 |
pulmonary vascular | 395 |
median duration | 395 |
three cases | 394 |
data collected | 394 |
blood culture | 394 |
creative commons | 394 |
neurocritical care | 393 |
congestive heart | 393 |
critical patients | 393 |
drug interactions | 393 |
first year | 393 |
cell counts | 392 |
risk assessment | 392 |
adverse outcomes | 392 |
first hours | 392 |
cardiovascular diseases | 391 |
three times | 391 |
medical record | 391 |
case fatality | 390 |
remains unclear | 390 |
mortality among | 390 |
may reduce | 390 |
high rate | 390 |
newly diagnosed | 390 |
squamous cell | 389 |
acute coronary | 389 |
gas exchange | 389 |
cell types | 389 |
chest radiography | 389 |
term outcomes | 388 |
dry cough | 388 |
respiratory illness | 388 |
patients reported | 387 |
internal medicine | 387 |
primary immunodeficiency | 387 |
six months | 386 |
early stages | 386 |
one month | 385 |
liver cirrhosis | 385 |
nephrotic syndrome | 385 |
may present | 385 |
healthy individuals | 384 |
viral clearance | 384 |
grade ii | 384 |
unrelated donor | 383 |
symptomatic patients | 383 |
immunosuppressive therapy | 383 |
health services | 383 |
infectious agents | 383 |
acute myeloid | 382 |
significant association | 382 |
prone position | 382 |
amino acids | 381 |
small sample | 381 |
flow nasal | 381 |
innate immunity | 380 |
female patients | 380 |
poor outcomes | 380 |
phase i | 380 |
control subjects | 380 |
corticosteroid therapy | 380 |
study conducted | 379 |
one week | 379 |
acute ischemic | 379 |
patient received | 378 |
intracranial pressure | 378 |
identify patients | 377 |
main outcome | 377 |
first step | 377 |
surgical mask | 376 |
hearing loss | 376 |
results finding | 376 |
covid patients | 375 |
risk stratification | 375 |
health status | 375 |
suspected covid | 375 |
neurological symptoms | 374 |
transfusion medicine | 373 |
remaining patients | 373 |
determined using | 373 |
copies ml | 373 |
american society | 373 |
european society | 373 |
defi ned | 372 |
time period | 372 |
nasopharyngeal swab | 372 |
preliminary data | 371 |
alveolar damage | 371 |
individual patient | 371 |
patient died | 371 |
ventilatory support | 370 |
patients affected | 370 |
blood stem | 370 |
age range | 369 |
broad spectrum | 369 |
corona virus | 369 |
arterial hypertension | 368 |
liver transplant | 368 |
icu mortality | 367 |
platelet counts | 367 |
increased levels | 366 |
young adults | 366 |
organ damage | 365 |
potential risk | 365 |
grade iii | 365 |
serious adverse | 365 |
study protocol | 365 |
key role | 364 |
will help | 363 |
blood volume | 363 |
compared using | 362 |
class ii | 362 |
antimicrobial resistance | 362 |
prothrombin time | 361 |
graft versus | 361 |
lung biopsy | 361 |
study shows | 360 |
low levels | 360 |
data regarding | 360 |
cell responses | 360 |
ground glass | 360 |
clinical significance | 359 |
human coronavirus | 359 |
studies suggest | 359 |
chronic disease | 359 |
showed significant | 359 |
airway management | 358 |
antiviral drugs | 358 |
least two | 358 |
also showed | 358 |
bariatric surgery | 358 |
may affect | 357 |
mycophenolate mofetil | 357 |
cd cell | 357 |
abstract background | 357 |
ct imaging | 357 |
small cell | 357 |
adaptive immune | 357 |
emergency medicine | 356 |
idiopathic pulmonary | 356 |
inflammatory mediators | 356 |
interim guidance | 356 |
patients whose | 354 |
may improve | 354 |
much higher | 354 |
endotracheal tube | 354 |
mg twice | 354 |
studies showed | 353 |
medical conditions | 353 |
expression levels | 353 |
acute exacerbation | 353 |
chest radiographs | 353 |
higher rate | 352 |
also reported | 351 |
mortality risk | 351 |
respiratory viral | 351 |
cerebrovascular disease | 350 |
care system | 350 |
patient presented | 350 |
coronavirus infections | 349 |
negative predictive | 349 |
high frequency | 349 |
acute lymphoblastic | 349 |
chronic renal | 349 |
neutropenic patients | 348 |
stage renal | 348 |
antibiotic resistance | 348 |
major cause | 348 |
laparoscopic surgery | 347 |
emergency departments | 347 |
antiviral activity | 347 |
otitis media | 347 |
group ii | 346 |
months later | 346 |
immune deficiency | 345 |
birth weight | 345 |
control groups | 345 |
significantly improved | 345 |
may represent | 344 |
health systems | 344 |
bile duct | 343 |
neurological manifestations | 343 |
kidney transplantation | 343 |
peritoneal dialysis | 343 |
cancer treatment | 343 |
lg ml | 343 |
also known | 343 |
plasminogen activator | 343 |
hematologic malignancies | 343 |
clinical study | 342 |
healthy donors | 341 |
evidence suggests | 341 |
many cases | 341 |
treatment strategies | 341 |
health commission | 341 |
three different | 341 |
respiratory virus | 341 |
springer nature | 341 |
antimicrobial agents | 340 |
care patients | 340 |
lung diseases | 340 |
healthcare systems | 339 |
reverse transcription | 339 |
jurisdictional claims | 338 |
negative patients | 338 |
institutional affiliations | 338 |
imaging features | 338 |
blood donor | 338 |
quality improvement | 338 |
published maps | 338 |
remains neutral | 337 |
nature remains | 337 |
infl uenza | 337 |
care settings | 336 |
stimulating factor | 336 |
available data | 336 |
cell culture | 336 |
less common | 336 |
corticosteroid treatment | 336 |
three days | 336 |
parenteral nutrition | 335 |
higher rates | 335 |
mean duration | 335 |
first line | 335 |
including patients | 335 |
line treatment | 335 |
radiation dose | 334 |
potential therapeutic | 334 |
operative time | 334 |
evaluated using | 334 |
secondary outcomes | 334 |
cell function | 333 |
room air | 333 |
may include | 333 |
vascular endothelial | 333 |
lung transplant | 333 |
adhesion molecules | 333 |
randomized trials | 333 |
carbon dioxide | 333 |
year survival | 333 |
clinical status | 332 |
nursing staff | 332 |
cell therapy | 332 |
versus host | 332 |
deep vein | 332 |
respiratory diseases | 332 |
treatment option | 332 |
clinical examination | 332 |
pcr testing | 332 |
drug therapy | 331 |
kg min | 331 |
clinical research | 331 |
younger patients | 331 |
clinical response | 330 |
herpes simplex | 330 |
mg daily | 330 |
clinical decision | 330 |
teaching hospital | 330 |
mass spectrometry | 330 |
patient satisfaction | 330 |
acute pulmonary | 330 |
specific ige | 329 |
virus infections | 329 |
prospective studies | 329 |
will require | 329 |
controlled study | 329 |
global pandemic | 329 |
protective effect | 329 |
will provide | 328 |
patient age | 328 |
patient groups | 328 |
vast majority | 328 |
fatty acids | 327 |
health professionals | 327 |
hematopoietic cell | 326 |
blood supply | 326 |
limited data | 326 |
neurological complications | 325 |
chronic pain | 325 |
partial pressure | 325 |
hubei province | 325 |
pathological findings | 325 |
colon cancer | 325 |
per minute | 325 |
square test | 325 |
propensity score | 325 |
infection may | 324 |
statistical analyses | 324 |
cardiovascular system | 324 |
thoracic surgery | 324 |
observational cohort | 323 |
expiratory pressure | 323 |
infected individuals | 323 |
data indicate | 323 |
antibiotic use | 323 |
may develop | 323 |
early phase | 323 |
study aims | 323 |
cancer care | 322 |
clinical setting | 322 |
single dose | 322 |
rectal cancer | 322 |
growth factors | 322 |
tyrosine kinase | 321 |
retrospective observational | 321 |
sars cov | 321 |
surgical procedure | 321 |
protein levels | 321 |
global health | 320 |
year follow | 320 |
molecular mechanisms | 320 |
macrophage activation | 319 |
supplementary material | 319 |
potential role | 319 |
nutritional status | 319 |
may need | 319 |
skin lesions | 319 |
patients also | 319 |
fio ratio | 319 |
receptor antagonist | 318 |
hazard ratio | 318 |
retrospective chart | 318 |
calculated using | 318 |
thoracic society | 318 |
host cells | 318 |
systolic blood | 318 |
center study | 318 |
consensus statement | 318 |
clinical evidence | 318 |
airway epithelial | 317 |
renal impairment | 317 |
chronic inflammatory | 316 |
pacientes con | 316 |
life support | 316 |
kawasaki disease | 316 |
autologous stem | 315 |
hepatic encephalopathy | 315 |
children aged | 315 |
patient data | 315 |
regression models | 315 |
higher prevalence | 315 |
generation sequencing | 315 |
pulmonary arterial | 315 |
high sensitivity | 315 |
clinical care | 315 |
transcription factor | 314 |
functional outcome | 314 |
thrombotic events | 314 |
tissue damage | 314 |
fl ow | 314 |
significant changes | 314 |
well established | 313 |
brain tissue | 313 |
community acquired | 313 |
severe coronavirus | 313 |
patient group | 313 |
also associated | 312 |
mean time | 312 |
postoperative day | 312 |
common symptoms | 311 |
underlying diseases | 311 |
positive pressure | 311 |
term outcome | 310 |
chronic lung | 309 |
clinical use | 309 |
diseases society | 309 |
significant risk | 309 |
wild type | 309 |
care services | 309 |
therapeutic strategies | 309 |
inflammatory responses | 309 |
complement activation | 309 |
laboratory parameters | 308 |
preventive measures | 308 |
group compared | 308 |
influenza infection | 308 |
angiotensin converting | 308 |
direct contact | 308 |
exome sequencing | 308 |
avian influenza | 307 |
cohort studies | 307 |
acute exacerbations | 307 |
autoimmune disease | 307 |
competing interests | 307 |
routine use | 306 |
intervention group | 306 |
high doses | 306 |
cmv reactivation | 306 |
lymphoblastic leukemia | 306 |
recently published | 306 |
years ago | 305 |
metabolic acidosis | 305 |
hodgkin lymphoma | 305 |
chronic respiratory | 305 |
high resolution | 305 |
troponin i | 304 |
organ transplant | 304 |
patient underwent | 304 |
cause mortality | 304 |
requiring mechanical | 303 |
standard treatment | 303 |
discharged home | 303 |
retrospective case | 303 |
health emergency | 303 |
glasgow coma | 303 |
cell cycle | 302 |
clinical information | 302 |
ct images | 302 |
within months | 302 |
tracheal intubation | 302 |
whole body | 301 |
negative results | 301 |
control patients | 301 |
coronary heart | 301 |
wound healing | 300 |
affected patients | 300 |
developing countries | 300 |
beneficial effects | 300 |
bloodstream infections | 299 |
pcr test | 299 |
animal model | 299 |
postoperative period | 298 |
mycoplasma pneumoniae | 298 |
clinical suspicion | 298 |
previous study | 298 |
care setting | 297 |
barr virus | 297 |
without permission | 297 |
atopic dermatitis | 297 |
pleural effusions | 297 |
marrow transplant | 297 |
analysed using | 297 |
pressure ventilation | 297 |
specific antibodies | 296 |
study will | 296 |
receptor blockers | 296 |
total body | 296 |
thromboembolic events | 296 |
factor viii | 296 |
induced lung | 295 |
positive end | 295 |
organ transplantation | 295 |
risk group | 295 |
fold increase | 295 |
cox regression | 294 |
cell receptor | 294 |
placebo group | 294 |
portal vein | 294 |
multidisciplinary team | 294 |
lung ultrasound | 294 |
chest wall | 293 |
reported cases | 293 |
better understanding | 293 |
relative risk | 293 |
kidney function | 293 |
emergency surgery | 293 |
intensity conditioning | 293 |
therapy may | 293 |
general surgery | 292 |
mild symptoms | 292 |
renal dysfunction | 292 |
hospitalised patients | 292 |
ct angiography | 292 |
pain management | 292 |
acute leukemia | 292 |
cmv infection | 291 |
immune reconstitution | 291 |
positive predictive | 291 |
allowed without | 291 |
reuse allowed | 291 |
reactive oxygen | 291 |
hepatic failure | 291 |
medical university | 290 |
therapeutic options | 290 |
positive airway | 290 |
platelet concentrates | 290 |
care professionals | 290 |
confidence intervals | 289 |
severe cap | 289 |
fungal infection | 289 |
first months | 289 |
safety profile | 289 |
every patient | 289 |
autosomal recessive | 289 |
independent predictor | 289 |
radiation exposure | 289 |
oxygen delivery | 289 |
successfully treated | 288 |
host immune | 288 |
systematic reviews | 288 |
hematological malignancies | 288 |
first week | 288 |
plasma therapy | 288 |
hemophagocytic lymphohistiocytosis | 287 |
note springer | 287 |
positive cells | 287 |
time point | 287 |
reduced intensity | 287 |
cardiopulmonary bypass | 286 |
one third | 286 |
negative bacteria | 286 |
myeloablative conditioning | 286 |
inflammatory cells | 286 |
hcv rna | 286 |
table shows | 286 |
mast cells | 285 |
severe symptoms | 285 |
disease caused | 285 |
pulmonary infection | 285 |
adverse drug | 284 |
patients experienced | 284 |
beneficial effect | 284 |
multivariate logistic | 284 |
brain death | 283 |
whenever possible | 283 |
similar results | 283 |
surgical resection | 283 |
severe infection | 282 |
plasma samples | 282 |
intubated patients | 282 |
hemolytic anemia | 282 |
female patient | 282 |
qt interval | 282 |
increased significantly | 282 |
complete blood | 282 |
muscle mass | 282 |
medical students | 282 |
immune function | 282 |
transfusion reactions | 282 |
times higher | 281 |
data show | 281 |
small intestine | 281 |
outcomes among | 281 |
severity score | 280 |
saudi arabia | 280 |
ace receptor | 280 |
male patient | 280 |
flow rate | 279 |
ulcerative colitis | 279 |
diagnostic testing | 279 |
median number | 279 |
enrolled patients | 279 |
cerebral edema | 279 |
hospital admissions | 278 |
deceased patients | 278 |
aspiration pneumonia | 278 |
multiorgan failure | 278 |
cancer cell | 278 |
opportunistic infections | 278 |
carotid artery | 278 |
frozen plasma | 277 |
two days | 277 |
radiological findings | 277 |
past years | 277 |
frequently used | 277 |
standard care | 277 |
blood mononuclear | 277 |
renal transplantation | 277 |
receiver operating | 277 |
taken together | 276 |
laboratory testing | 276 |
human metapneumovirus | 276 |
serum ferritin | 276 |
imaging studies | 276 |
solid tumors | 276 |
fresh frozen | 276 |
intracerebral hemorrhage | 276 |
advanced age | 276 |
low molecular | 276 |
crp levels | 276 |
crucial role | 275 |
success rate | 275 |
lower risk | 275 |
acute pancreatitis | 275 |
treatment failure | 275 |
clinical picture | 275 |
abdominal wall | 275 |
study reported | 275 |
weight heparin | 274 |
may explain | 274 |
south korea | 274 |
missing data | 274 |
graft survival | 274 |
intravenous drip | 274 |
umbilical cord | 274 |
independent predictors | 273 |
strongly associated | 273 |
clinical evaluation | 273 |
least days | 273 |
relatively low | 273 |
examination revealed | 273 |
worse outcomes | 273 |
social media | 273 |
severe hepatitis | 272 |
glomerular filtration | 272 |
better understand | 272 |
altered mental | 272 |
immune cell | 272 |
past medical | 272 |
clinical experience | 272 |
clinical benefit | 272 |
rank test | 272 |
prognostic factor | 272 |
liver biopsy | 272 |
invasive aspergillosis | 272 |
matched unrelated | 271 |
data will | 271 |
short term | 271 |
plasma cells | 271 |
pulmonary complications | 271 |
lower extremity | 271 |
term survival | 271 |
antibody responses | 271 |
hospital length | 271 |
coagulation parameters | 271 |
clostridium difficile | 271 |
pulmonary infiltrates | 271 |
results obtained | 271 |
correlation coefficient | 271 |
nuclear medicine | 270 |
room temperature | 270 |
older people | 270 |
false positive | 270 |
common cold | 270 |
line therapy | 269 |
high rates | 269 |
improve patient | 269 |
greater risk | 269 |
airway obstruction | 269 |
failure assessment | 268 |
hospital death | 268 |
retrospectively analyzed | 268 |
new zealand | 268 |
imaging modalities | 268 |
intracranial hemorrhage | 268 |
laparoscopic approach | 267 |
study using | 267 |
descriptive statistics | 267 |
increased incidence | 267 |
european countries | 267 |
asthma control | 267 |
may become | 267 |
immune dysregulation | 267 |
results demonstrate | 267 |
hemodynamic instability | 267 |
oxygen species | 267 |
risk score | 266 |
electronic health | 266 |
portal hypertension | 266 |
serum albumin | 266 |
chinese center | 265 |
renal insufficiency | 265 |
mortality due | 265 |
pediatric population | 264 |
neutrophil count | 264 |
within weeks | 264 |
first day | 264 |
increased expression | 264 |
current evidence | 264 |
severe forms | 264 |
angiotensin system | 264 |
higher proportion | 264 |
pulse oximetry | 264 |
performance status | 264 |
current pandemic | 263 |
blood tests | 263 |
trend towards | 263 |
saps ii | 263 |
closely related | 262 |
complete response | 262 |
patients present | 262 |
gastric bypass | 262 |
elevated serum | 262 |
inflammatory diseases | 262 |
vascular disease | 262 |
considered statistically | 261 |
face mask | 261 |
stroke patients | 261 |
severe infections | 261 |
clinical condition | 261 |
invasive fungal | 260 |
lessons learned | 260 |
progressive disease | 260 |
international guidelines | 260 |
please specify | 260 |
th cells | 260 |
drug resistance | 260 |
among children | 260 |
information regarding | 260 |
outpatient clinic | 259 |
th percentile | 259 |
million people | 259 |
many countries | 259 |
clinical deterioration | 259 |
tidal volumes | 259 |
inflammatory cytokine | 259 |
urine output | 259 |
upper airway | 259 |
functional status | 259 |
significantly elevated | 259 |
vena cava | 259 |
confl ict | 259 |
old girl | 259 |
early treatment | 258 |
randomized study | 258 |
relatively high | 258 |
study found | 258 |
plasma exchange | 258 |
treatment groups | 258 |
care team | 258 |
time spent | 258 |
severe complications | 258 |
severe sars | 258 |
ill patient | 258 |
steroid therapy | 257 |
fi brosis | 257 |
old boy | 257 |
admitted patients | 257 |
successful treatment | 257 |
also performed | 257 |
diagnostic tool | 257 |
complication rate | 257 |
every hours | 257 |
icu discharge | 256 |
glucose levels | 256 |
previous reports | 256 |
chronic inflammation | 256 |
clinical parameters | 256 |
hbv infection | 256 |
days prior | 256 |
study also | 256 |
published data | 255 |
high grade | 255 |
acute graft | 255 |
plasma concentrations | 255 |
acute stroke | 255 |
antiretroviral therapy | 255 |
physical exam | 255 |
like symptoms | 255 |
extracellular matrix | 255 |
combined immunodeficiency | 255 |
signal intensity | 254 |
en pacientes | 254 |
investigate whether | 254 |
team members | 254 |
uric acid | 254 |
clinical efficacy | 254 |
accepted article | 254 |
ace inhibitors | 254 |
organizing pneumonia | 254 |
abstract type | 254 |
clinical relevance | 253 |
clinical impact | 253 |
host cell | 253 |
reverse transcriptase | 253 |
often associated | 253 |
peripheral neuropathy | 253 |
may benefit | 253 |
pediatric intensive | 253 |
will continue | 253 |
inflammatory drugs | 253 |
may reflect | 253 |
less severe | 253 |
north america | 252 |
vascular resistance | 252 |
individual patients | 252 |
cd expression | 252 |
clinical presentations | 252 |
cardiac function | 251 |
dependent manner | 251 |
respiratory pathogens | 251 |
enteral nutrition | 251 |
host response | 250 |
within normal | 250 |
platelet aggregation | 250 |
three years | 250 |
surgery patients | 250 |
among covid | 250 |
roc curve | 250 |
foreign body | 250 |
gene therapy | 250 |
clinical isolates | 250 |
glycemic control | 250 |
viral loads | 250 |
significantly correlated | 250 |
protease inhibitor | 249 |
generating procedures | 249 |
bacterial pathogens | 249 |
blood product | 249 |
activated charcoal | 249 |
epithelial cell | 249 |
clinical conditions | 249 |
also present | 249 |
heart association | 249 |
coronavirus pandemic | 249 |
included studies | 249 |
analysis using | 249 |
neutralizing antibodies | 249 |
thrombotic microangiopathy | 249 |
spontaneous breathing | 249 |
liver enzymes | 249 |
cox proportional | 248 |
blood collection | 248 |
nursing home | 248 |
gestational age | 248 |
pcr assay | 248 |
klebsiella pneumoniae | 248 |
treat patients | 248 |
airway inflammation | 248 |
term care | 248 |
confi rmed | 247 |
health insurance | 247 |
based study | 247 |
inspired oxygen | 247 |
will allow | 247 |
pulmonary rehabilitation | 247 |
creatinine clearance | 247 |
fluid resuscitation | 246 |
early identification | 246 |
fluid balance | 246 |
icu care | 246 |
unrelated donors | 246 |
group received | 246 |
month follow | 246 |
income countries | 246 |
brain mri | 246 |
imaging techniques | 245 |
increasing number | 245 |
study suggests | 245 |
also used | 245 |
increased susceptibility | 245 |
cardiovascular events | 244 |
several days | 244 |
recombinant human | 244 |
laboratory results | 244 |
urgent need | 244 |
following criteria | 244 |
infections caused | 244 |
useful tool | 244 |
trauma center | 243 |
also significantly | 243 |
lymphocyte subsets | 243 |
disease status | 243 |
infected cells | 243 |
lung parenchyma | 243 |
prospectively collected | 243 |
among hospitalized | 243 |
improved survival | 243 |
host defense | 242 |
important factor | 242 |
four cases | 242 |
sleep apnea | 242 |
hypertonic saline | 242 |
clinical assessment | 242 |
seasonal influenza | 242 |
financial support | 242 |
coagulation factors | 242 |
conditioning regimens | 241 |
coma scale | 241 |
studies reported | 241 |
therapeutic option | 241 |
demographic characteristics | 241 |
false negative | 241 |
venous catheter | 241 |
cardiac involvement | 241 |
several limitations | 241 |
cardiac disease | 241 |
biopsy specimens | 241 |
filtration rate | 241 |
contact tracing | 241 |
gastrointestinal bleeding | 240 |
prospective randomized | 240 |
submitted work | 240 |
natriuretic peptide | 240 |
medical therapy | 240 |
lower mortality | 240 |
per week | 240 |
donor chimerism | 240 |
icu length | 240 |
critical role | 240 |
resistant bacteria | 240 |
risk groups | 240 |
viral hepatitis | 240 |
ethics regulations | 239 |
right heart | 239 |
young patients | 239 |
diagnostic value | 239 |
compassionate use | 239 |
cerebral blood | 239 |
surgical management | 239 |
next generation | 239 |
disease process | 239 |
high flow | 239 |
initial treatment | 239 |
drug reactions | 238 |
activation syndrome | 238 |
metastatic disease | 238 |
poorly understood | 238 |
fold higher | 238 |
side effect | 238 |
healthcare facilities | 238 |
extremely rare | 238 |
body fluids | 238 |
failure due | 238 |
medical management | 237 |
cardiovascular complications | 237 |
high quality | 237 |
hypercoagulable state | 237 |
respiratory function | 237 |
among others | 237 |
antiphospholipid antibodies | 236 |
spectrum antibiotics | 236 |
lung damage | 236 |
cfu ml | 236 |
influenza viruses | 236 |
seven days | 235 |
first report | 235 |
los pacientes | 235 |
study demonstrated | 235 |
health outcomes | 235 |
first study | 235 |
health service | 235 |
acute cardiac | 235 |
coronary syndrome | 235 |
comorbid conditions | 235 |
diffi cult | 235 |
mean follow | 235 |
respiratory secretions | 234 |
university medical | 234 |
signaling pathway | 234 |
genetic testing | 234 |
chronic rhinosinusitis | 234 |
alanine aminotransferase | 234 |
cell entry | 234 |
national institutes | 233 |
cell subsets | 233 |
creatine kinase | 233 |
significant impact | 233 |
therapeutic approach | 233 |
blood transfusions | 233 |
differ significantly | 233 |
lymphocyte counts | 233 |
bladder cancer | 232 |
less frequently | 232 |
transplanted patients | 232 |
chronic bronchitis | 232 |
randomly assigned | 232 |
significantly greater | 232 |
care delivery | 232 |
platelet activation | 232 |
med doi | 232 |
adhesion molecule | 232 |
comparative study | 232 |
renal biopsy | 232 |
contrast enhancement | 231 |
major role | 231 |
treated group | 231 |
germ cell | 231 |
blood banks | 231 |
platelet transfusion | 231 |
graft function | 231 |
patient demographics | 231 |
rna polymerase | 231 |
mean value | 231 |
neck cancer | 231 |
previously healthy | 230 |
sequential organ | 230 |
predictive factors | 230 |
stromal cells | 230 |
current covid | 230 |
groups according | 230 |
pneumonia caused | 230 |
significantly less | 230 |
requiring hospitalization | 230 |
mycobacterium tuberculosis | 230 |
improve outcomes | 230 |
life threatening | 230 |
american heart | 230 |
important lessons | 230 |
early recognition | 230 |
paediatric patients | 230 |
surgical masks | 230 |
healthcare personnel | 230 |
hypoxemic respiratory | 230 |
artery bypass | 229 |
open access | 229 |
antibody response | 229 |
five years | 229 |
appropriate treatment | 229 |
blood sample | 229 |
viral entry | 229 |
initial presentation | 229 |
disease onset | 229 |
transmission dynamics | 229 |
infection rates | 228 |
oral cavity | 228 |
pressure support | 228 |
many studies | 228 |
moderate covid | 228 |
relapse mortality | 228 |
patients often | 228 |
will likely | 228 |
response syndrome | 228 |
grade i | 228 |
preliminary report | 228 |
assess whether | 228 |
injured patients | 227 |
cirrhotic patients | 227 |
patient populations | 227 |
autosomal dominant | 227 |
common causes | 226 |
laboratory values | 226 |
new onset | 226 |
readily available | 226 |
eligible patients | 226 |
mild disease | 226 |
positive cases | 226 |
mean difference | 226 |
patients enrolled | 226 |
patient survival | 226 |
cancer surgery | 225 |
five cases | 225 |
data obtained | 225 |
immune checkpoint | 225 |
incidence rate | 225 |
pulmonary involvement | 225 |
kg iv | 225 |
medical patients | 225 |
thromboembolic complications | 225 |
days following | 225 |
positively correlated | 225 |
lower levels | 225 |
critical covid | 224 |
imaging modality | 224 |
surface area | 224 |
cardiac troponin | 224 |
limited number | 224 |
active disease | 224 |
differentially expressed | 224 |
target cells | 224 |
invasive procedures | 224 |
mainly due | 224 |
time course | 224 |
positive blood | 224 |
several factors | 224 |
recurrent infections | 223 |
se recomienda | 223 |
leydig cells | 223 |
operating characteristic | 223 |
cd ra | 223 |
progenitor cells | 223 |
adult respiratory | 223 |
reperfusion injury | 223 |
significant morbidity | 223 |
guidelines recommend | 222 |
coronavirus outbreak | 222 |
hernia repair | 222 |
case study | 222 |
cell depletion | 222 |
massive transfusion | 222 |
one patients | 222 |
transfusion service | 222 |
staff members | 222 |
pneumonia patients | 222 |
patients within | 221 |
hospital setting | 221 |
rheumatic diseases | 221 |
cytokine levels | 221 |
available evidence | 221 |
chest tube | 221 |
treatment response | 221 |
eye protection | 221 |
statistical difference | 221 |
resistant strains | 221 |
susceptibility testing | 221 |
plasma membrane | 221 |
controlled clinical | 221 |
secondary bacterial | 220 |
severe clinical | 220 |
treatment may | 220 |
considered significant | 220 |
disease may | 220 |
different clinical | 220 |
receptor binding | 220 |
central role | 220 |
center experience | 220 |
daily living | 220 |
venous blood | 220 |
previously published | 220 |
patients referred | 220 |
two months | 219 |
continuous infusion | 219 |
like receptor | 219 |
angiotensin receptor | 219 |
face shield | 219 |
first reported | 219 |
lung involvement | 219 |
worse prognosis | 219 |
head injury | 219 |
healthcare settings | 219 |
specific cd | 219 |
day post | 219 |
shock patients | 218 |
antiviral agents | 218 |
infection risk | 218 |
glucose tolerance | 218 |
expert consensus | 218 |
weight gain | 218 |
surviving sepsis | 218 |
healthy control | 218 |
hydrogen peroxide | 218 |
first two | 218 |
partial thromboplastin | 218 |
coronary angiography | 218 |
signaling pathways | 217 |
western blotting | 217 |
conservative treatment | 217 |
flow oxygen | 217 |
viral particles | 217 |
tissue factor | 217 |
interventional radiology | 217 |
consecutive days | 217 |
liver damage | 217 |
two independent | 217 |
cardiac index | 217 |
cell adhesion | 217 |
patient selection | 216 |
clinical settings | 216 |
using standard | 216 |
low level | 216 |
injury severity | 216 |
high fever | 216 |
targeted therapy | 216 |
studied patients | 216 |
positive result | 216 |
lymphocyte ratio | 215 |
identified patients | 215 |
clinical history | 215 |
renal cell | 215 |
artificial intelligence | 215 |
ischemic heart | 215 |
additional information | 215 |
sedimentation rate | 215 |
therapeutic hypothermia | 215 |
large cohort | 214 |
lavage fluid | 214 |
liver dysfunction | 214 |
blood gases | 214 |
probably due | 214 |
mhc class | 214 |
systemic sclerosis | 213 |
wide variety | 213 |
cardiopulmonary resuscitation | 213 |
healthy children | 213 |
hemorrhagic shock | 213 |
diagnostic test | 213 |
thromboplastin time | 213 |
associated infections | 213 |
fatty acid | 213 |
radiographic findings | 213 |
two studies | 213 |
immunosuppressed patients | 213 |
syndrome associated | 213 |
blood donations | 213 |
nursing homes | 213 |
bronchiolitis obliterans | 213 |
antiphospholipid syndrome | 213 |
person transmission | 212 |
quality assurance | 212 |
ncov infection | 212 |
likely due | 212 |
abdominal surgery | 212 |
obstructive sleep | 212 |
human coronaviruses | 212 |
american thoracic | 212 |
care hospital | 212 |
fatty liver | 212 |
suspected cases | 212 |
life expectancy | 212 |
food allergy | 212 |
second group | 212 |
dose reduction | 212 |
inflammatory process | 211 |
higher level | 211 |
simplex virus | 211 |
alveolar macrophages | 211 |
health problem | 211 |
lower limb | 211 |
thrombocytopenic purpura | 211 |
routine clinical | 211 |
mcg kg | 211 |
ill adults | 211 |
cancer center | 211 |
using spss | 211 |
residual disease | 211 |
infection rate | 211 |
allergic reactions | 211 |
fdg pet | 210 |
time reverse | 210 |
may indicate | 210 |
dose chemotherapy | 210 |
five days | 210 |
mean number | 210 |
management strategies | 210 |
good outcome | 210 |
accurate diagnosis | 210 |
liver fibrosis | 210 |
specific treatment | 210 |
neurologic manifestations | 209 |
ace receptors | 209 |
patients years | 209 |
febrile neutropenia | 209 |
data set | 209 |
many years | 209 |
igg antibodies | 209 |
igg levels | 209 |
also important | 209 |
muscle cells | 209 |
hiv patients | 209 |
related quality | 209 |
data available | 208 |
severe combined | 208 |
patienten mit | 208 |
cells may | 208 |
health authorities | 208 |
may serve | 208 |
loading dose | 208 |
care facility | 208 |
cell source | 208 |
median survival | 208 |
significantly better | 208 |
viral respiratory | 208 |
significant proportion | 208 |
activated protein | 207 |
gel electrophoresis | 207 |
first group | 207 |
serum concentrations | 207 |
neutrophil extracellular | 207 |
surgical site | 207 |
cell membrane | 206 |
vitro studies | 206 |
liver diseases | 206 |
situ hybridization | 206 |
spontaneous pneumothorax | 206 |
transplant recipient | 206 |
average time | 206 |
common clinical | 206 |
chronic lymphocytic | 206 |
influenza pneumonia | 206 |
none declared | 206 |
sepsis campaign | 206 |
one day | 206 |
therapeutic anticoagulation | 206 |
brain barrier | 205 |
study demonstrates | 205 |
randomly selected | 205 |
sputum samples | 205 |
cerebral artery | 205 |
high morbidity | 205 |
asthmatic patients | 205 |
promising results | 205 |
unclear whether | 205 |
contrast agent | 205 |
influenza vaccination | 205 |
adverse effect | 205 |
haematopoietic stem | 205 |
pulmonary tuberculosis | 204 |
bacterial contamination | 204 |
time rt | 204 |
protein kinase | 204 |
studies will | 204 |
antibody titers | 204 |
significant effect | 204 |
induction therapy | 204 |
chest computed | 204 |
every day | 204 |
oral administration | 203 |
new cases | 203 |
abnormal coagulation | 203 |
tumor size | 203 |
smoking cessation | 203 |
sleeve gastrectomy | 203 |
develop severe | 203 |
protease inhibitors | 203 |
bal fluid | 203 |
might also | 203 |
final diagnosis | 203 |
cases per | 203 |
blood units | 203 |
also occur | 203 |
low grade | 203 |
hcv infection | 203 |
serious complications | 203 |
tertiary hospital | 202 |
close monitoring | 202 |
first patient | 202 |
patients due | 202 |
cancer therapy | 202 |
respiratory specimens | 202 |
respiratory droplets | 202 |
confirmed sars | 202 |
emergency use | 202 |
hsct recipients | 202 |
bloodstream infection | 202 |
clinical severity | 202 |
intracranial hypertension | 202 |
stable patients | 202 |
odds ratios | 201 |
negative impact | 201 |
partial response | 201 |
year os | 201 |
remains controversial | 201 |
patient showed | 201 |
last decade | 201 |
post transplant | 201 |
developed acute | 200 |
highest risk | 200 |
oral health | 200 |
must also | 200 |
recent data | 200 |
treatment protocol | 200 |
adults hospitalized | 200 |
within one | 200 |
done using | 200 |
outcome measure | 200 |
high number | 200 |
cardiac dysfunction | 200 |
march th | 200 |
nucleic acids | 200 |
peripheral nerve | 200 |
medical school | 200 |
normal saline | 200 |
within minutes | 200 |
needle aspiration | 199 |
often used | 199 |
aspartate aminotransferase | 199 |
short period | 199 |
tissue samples | 199 |
glass opacity | 199 |
therapeutic approaches | 199 |
acute appendicitis | 199 |
may vary | 199 |
health problems | 199 |
continuous positive | 199 |
acute physiology | 199 |
clinical manifestation | 199 |
postoperative pain | 199 |
may influence | 199 |
decreased significantly | 198 |
higher among | 198 |
protective measures | 198 |
lower lobe | 198 |
back pain | 198 |
severe form | 198 |
health workers | 198 |
presenting symptoms | 198 |
primary pulmonary | 198 |
ovarian cancer | 198 |
cell response | 198 |
two types | 197 |
current guidelines | 197 |
patients must | 197 |
stage iii | 197 |
mean values | 197 |
important cause | 197 |
maintenance therapy | 197 |
con covid | 197 |
commonly seen | 197 |
emergency medical | 197 |
main cause | 197 |
sample collection | 197 |
hiv aids | 197 |
practice guideline | 197 |
narrative review | 197 |
last months | 197 |
physical therapy | 197 |
urine samples | 197 |
four groups | 197 |
therapeutic strategy | 197 |
gi tract | 196 |
binding protein | 196 |
type iii | 196 |
patient outcome | 196 |
signal transduction | 196 |
induced thrombocytopenia | 196 |
drug use | 196 |
acute bronchitis | 196 |
gut microbiota | 196 |
future research | 196 |
effi cacy | 196 |
therapeutic target | 196 |
new therapeutic | 196 |
patients taking | 196 |
nosocomial pneumonia | 196 |
investigated whether | 196 |
enteral feeding | 195 |
alkaline phosphatase | 195 |
observation period | 195 |
treatment guidelines | 195 |
negative correlation | 195 |
related adverse | 195 |
cells expressing | 195 |
neuromuscular blockade | 195 |
mcg ml | 195 |
epidemiological characteristics | 194 |
usual care | 194 |
retrospective studies | 194 |
patient may | 194 |
outcome data | 194 |
highly sensitive | 194 |
treating patients | 194 |
genomic dna | 194 |
test result | 194 |
operation time | 194 |
data sets | 194 |
tested negative | 194 |
special attention | 194 |
severe community | 194 |
haemophilus influenzae | 194 |
giant cell | 194 |
pulmonary aspergillosis | 193 |
spatial resolution | 193 |
data showed | 193 |
reduce mortality | 193 |
severe influenza | 193 |
therapeutic interventions | 193 |
introduction background | 193 |
throat swab | 193 |
upper limit | 193 |
face masks | 193 |
iron deficiency | 193 |
median length | 193 |
muscle strength | 193 |
one hour | 193 |
supine position | 193 |
human transmission | 193 |
least months | 193 |
cell viability | 192 |
cd count | 192 |
death rate | 192 |
good clinical | 192 |
ill icu | 192 |
epidemiological data | 192 |
relatively small | 192 |
bowel obstruction | 192 |
erythrocyte sedimentation | 192 |
standard therapy | 192 |
without evidence | 191 |
clinical criteria | 191 |
subgroup analysis | 191 |
nationwide analysis | 191 |
findings may | 191 |
remained stable | 191 |
without significant | 191 |
well documented | 191 |
short time | 191 |
ventricular dysfunction | 191 |
high degree | 191 |
treatment modalities | 191 |
stage i | 190 |
wide spectrum | 190 |
required mechanical | 190 |
less frequent | 190 |
multivariable logistic | 190 |
adaptive immunity | 190 |
urea nitrogen | 190 |
large vessel | 190 |
tissue injury | 190 |
survival benefit | 190 |
results may | 190 |
gram negative | 190 |
factor receptor | 190 |
nutritional support | 190 |
multivariable analysis | 190 |
patients transplanted | 190 |
died due | 189 |
failure requiring | 189 |
studies using | 189 |
last follow | 189 |
male sex | 189 |
patients following | 189 |
per cent | 189 |
american academy | 189 |
inflammatory disease | 189 |
phase trial | 189 |
major risk | 189 |
nerve conduction | 189 |
group patients | 189 |
chest imaging | 189 |
showed significantly | 189 |
kg body | 189 |
extracellular traps | 188 |
treatment strategy | 188 |
will discuss | 188 |
thromboembolic disease | 188 |
studies show | 188 |
transcription factors | 188 |
lactate levels | 188 |
adjuvant chemotherapy | 188 |
end stage | 188 |
venous catheters | 188 |
muscle weakness | 188 |
limited resources | 188 |
environmental factors | 188 |
previously shown | 188 |
right ventricle | 188 |
binding domain | 188 |
venous pressure | 188 |
particularly important | 188 |
significant change | 188 |
complications associated | 188 |
head ct | 188 |
laparoscopic cholecystectomy | 188 |
hospital day | 187 |
clinical specimens | 187 |
significant number | 187 |
negative bacilli | 187 |
mechanisms underlying | 187 |
using two | 187 |
examination showed | 187 |
recently reported | 187 |
treat covid | 187 |
procedure details | 187 |
common complication | 187 |
response rates | 187 |
literature search | 187 |
transforming growth | 187 |
patients develop | 187 |
hospital cardiac | 187 |
arterial oxygen | 187 |
hand washing | 187 |
fatal outcome | 187 |
ms patients | 187 |
skin prick | 186 |
factors may | 186 |
specific antibody | 186 |
developed severe | 186 |
ischaemic stroke | 186 |
study including | 186 |
northern italy | 186 |
blood center | 186 |
younger age | 186 |
disease transmission | 186 |
oncology patients | 185 |
left ventricle | 185 |
ventricular function | 185 |
sertoli cells | 185 |
therapeutic intervention | 185 |
anticoagulant therapy | 185 |
severe pulmonary | 185 |
highly contagious | 185 |
family member | 185 |
asthma exacerbations | 185 |
icu beds | 185 |
ferritin levels | 185 |
diagnostic yield | 184 |
suspected patients | 184 |
enzyme inhibitors | 184 |
illness severity | 184 |
best practices | 184 |
cell populations | 184 |
pneumococcal pneumonia | 184 |
coronavirus sars | 184 |
operating rooms | 184 |
decreased mortality | 184 |
african american | 184 |
emergency physicians | 184 |
therapeutic effect | 183 |
atypical pneumonia | 183 |
classified according | 183 |
locally advanced | 183 |
expression level | 183 |
deep venous | 183 |
skull base | 183 |
expert opinion | 183 |
information system | 183 |
acinetobacter baumannii | 183 |
stroke volume | 183 |
nasopharyngeal swabs | 183 |
eleven patients | 183 |
took place | 183 |
following treatment | 183 |
infection among | 183 |
qt prolongation | 183 |
normal values | 183 |
group showed | 183 |
haematological malignancies | 183 |
best practice | 183 |
cases showed | 183 |
take place | 183 |
normal controls | 182 |
endoplasmic reticulum | 182 |
mm patients | 182 |
lung volume | 182 |
secondary infection | 182 |
aldosterone system | 182 |
study provides | 182 |
medical personnel | 182 |
treatment regimens | 182 |
several clinical | 182 |
daily dose | 182 |
continuous renal | 182 |
cells showed | 181 |
blood component | 181 |
possible role | 181 |
mast cell | 181 |
immune complexes | 181 |
antifungal therapy | 181 |
many different | 181 |
multiplex pcr | 180 |
head trauma | 180 |
higher doses | 180 |
parainfluenza virus | 180 |
standard precautions | 180 |
also included | 180 |
medical education | 180 |
significant role | 180 |
ibd patients | 180 |
long time | 180 |
middle ear | 180 |
one hand | 180 |
invasive surgery | 180 |
deficient mice | 180 |
supplementary table | 180 |
proportional hazards | 180 |
published studies | 180 |
hours post | 179 |
single centre | 179 |
academic medical | 179 |
animal studies | 179 |
widespread use | 179 |
organ systems | 179 |
coronary arteries | 179 |
experimental studies | 179 |
activated partial | 179 |
different levels | 179 |
neutralizing antibody | 179 |
clinic visits | 179 |
mri findings | 179 |
traditional chinese | 178 |
lower extremities | 178 |